Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases.

Bay Area-based CytomX and Astellas forged a strategic relationship worth up to more than $1.6 billion to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.

AcelRx Pharmaceuticals of Redwood City, California, is buying Watertown, Massachusetts-based TetraPhase Pharmaceuticals for $14.4 million.

Thermo Fisher Scientific inked a deal with Janssen Biotech, part of Johnson & Johnson, to co-develop a companion diagnostic for cancer. The diagnostic test will support global clinical trial enrollment.

Nearly two months after inking a licensing deal worth up to $1.5 billion with Swiss pharma giant Roche, Amunix Pharmaceuticals secured $73 million in an oversubscribed Series A financing round that will support the development of the company’s pipeline of novel T cell engagers (XPATs) and cytokines (XPACs).

Biogen and Sangamo Therapeutics announced a broad global licensing collaboration deal to develop and commercialize several compounds for a range of neurological and neuromuscular diseases.

Three years after Takeda Pharmaceutical and PvP Biologics inked a $35 million deal to develop a novel treatment for celiac disease, the Japanese pharma manufacturer exercised an option to acquire the San Diego-based company for $330 million.

As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.

KalVista Pharmaceuticals indicated that Merck had allowed the option deal between the companies for the intravitreal diabetic macular edema (IDME) drug KVD001 and future DME molecules to expire.

CURE Pharmaceutical, an innovative drug delivery and development company, signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products.